Scientists from A*STAR Institute of Molecular and Cell Biology (A*STAR IMCB) have identified why certain lung cancer cells ...

Dr Mark Kris discusses the increasing precision of lung cancer therapies and the need for additional testing to find ...

In a media release on Jan. 22, it was revealed that a group of scientists from the Agency for Science, Technology and ...

Afatinib almost doubled progression-free survival versus chemotherapy in advanced lung cancer with uncommon EGFR mutations. The treatment effect was consistent across major uncommon mutations, ...

The US Food and Drug Administration (FDA) today approved the first blood-based genetic test that can detect epidermal growth factor receptor (EGFR) gene mutations in non-small cell lung cancer ...

Yesterday, the U.S. Food and Drug Administration approved the first blood-based genetic test that can detect gene mutations in non-small cell lung cancer patients. The cobas EGFR Mutation Test v2 is a ...

Large cell carcinoma is aggressive, requiring early detection through imaging and biopsy for optimal treatment outcomes.

While the statistics remain stark—lung cancer is the most common type of cancer worldwide and has the highest death ...

Scientists from A*STAR Institute of Molecular and Cell Biology (A*STAR IMCB) have identified why certain lung cancer cells become highly resistant to treatment after developing mutations in a key gene ...

When the team knocked out the P2Y2 receptor in drug-resistant cancer cells, it led to an almost complete loss of the mutant EGFR protein.